Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening
- PMID: 23269114
- PMCID: PMC3604989
- DOI: 10.1097/MLR.0b013e31827da979
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening
Abstract
Background: The US Preventive Services Task Force recently recommended against prostate-specific antigen screening for prostate cancer based primarily on evidence from the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial.
Objective: : To examine limitations of basing screening policy on evidence from screening trials.
Methods: We reviewed published modeling studies that examined population and trial data. The studies (1) project the roles of screening and changes in primary treatment in the US mortality decline; (2) extrapolate the ERSPC mortality reduction to the long-term US setting; (3) estimate overdiagnosis based on US incidence trends; and (4) quantify the impact of control arm screening on PLCO mortality results.
Results: Screening plausibly explains 45% and changes in primary treatment can explain 33% of the US prostate cancer mortality decline. Extrapolating the ERSPC results to the long-term US setting implies an absolute mortality reduction at least 5 times greater than that observed in the trial. Approximately 28% of screen-detected cases are overdiagnosed in the United States versus 58% of screen-detected cases suggested by the ERSPC results. Control arm screening can explain the null result in the PLCO trial.
Conclusions: Modeling studies indicate that population trends and trial results extended to the long-term population setting are consistent with greater benefit of prostate-specific antigen screening-and more favorable harm-benefit tradeoffs-than has been suggested by empirical trial evidence.
Comment in
-
Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening.Med Care. 2013 Apr;51(4):301-3. doi: 10.1097/MLR.0b013e31828a67d3. Med Care. 2013. PMID: 23481031
Similar articles
-
Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening.Med Care. 2013 Apr;51(4):301-3. doi: 10.1097/MLR.0b013e31828a67d3. Med Care. 2013. PMID: 23481031
-
The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6. Cancer. 2018. PMID: 29211316 Free PMC article.
-
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5. Ann Intern Med. 2017. PMID: 28869989 Free PMC article.
-
Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.World J Urol. 2012 Apr;30(2):137-42. doi: 10.1007/s00345-011-0799-4. Epub 2011 Nov 25. World J Urol. 2012. PMID: 22116599 Review.
-
Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Can J Urol. 2005. PMID: 15780157 Review.
Cited by
-
[PSA screening 2013: background and perspectives].Urologe A. 2014 Jun;53(6):875-81. doi: 10.1007/s00120-013-3193-6. Urologe A. 2014. PMID: 23712424 German.
-
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients.EJNMMI Phys. 2019 Jan 11;6(1):2. doi: 10.1186/s40658-018-0239-2. EJNMMI Phys. 2019. PMID: 30631980 Free PMC article.
-
Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era.Sci Rep. 2024 Mar 9;14(1):5810. doi: 10.1038/s41598-024-55859-z. Sci Rep. 2024. PMID: 38461151 Free PMC article.
-
Personalized early detection and prevention of breast cancer: ENVISION consensus statement.Nat Rev Clin Oncol. 2020 Nov;17(11):687-705. doi: 10.1038/s41571-020-0388-9. Epub 2020 Jun 18. Nat Rev Clin Oncol. 2020. PMID: 32555420 Free PMC article. Review.
-
Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial.Med Decis Making. 2020 Nov;40(8):1034-1040. doi: 10.1177/0272989X20961095. Epub 2020 Oct 20. Med Decis Making. 2020. PMID: 33078673 Free PMC article. Clinical Trial.
References
-
- Moyer VA, on behalf of the USPSTF Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012 - PubMed
-
- Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical